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1. INTRODUCTION {#brb3974-sec-0005}
===============

The efficacy of endovascular treatment (ET) versus medical treatment alone in patients with stroke caused by occlusion of the middle cerebral artery or the internal carotid artery has been proven in several randomized studies (Berkhemer et al., [2015](#brb3974-bib-0003){ref-type="ref"}; Campbell et al., [2015](#brb3974-bib-0008){ref-type="ref"}; Goyal et al., [2015a](#brb3974-bib-0012){ref-type="ref"}; Molina et al., [2015](#brb3974-bib-0016){ref-type="ref"}; Saver et al., [2015](#brb3974-bib-0021){ref-type="ref"}). The use of mechanical thrombectomy has gradually spread since 2004, when the first retriever device was approved for endovascular treatment in stroke patients (Smith et al., [2005](#brb3974-bib-0023){ref-type="ref"}). In subsequent years, a number of various endovascular device systems (Penumbra aspiration, stent retriever) have been approved (Nogueira et al., [2012](#brb3974-bib-0018){ref-type="ref"}; Penumbra Pivotal Stroke Trial I, [2009](#brb3974-bib-0019){ref-type="ref"}; Saver et al., [2012](#brb3974-bib-0022){ref-type="ref"}).

Several recent randomized trials of endovascular treatment for AIS showed reduced disability among stroke patients who were treated with ET in addition to standard IV rt‐PA (Berkhemer et al., [2015](#brb3974-bib-0003){ref-type="ref"}; Campbell et al., [2015](#brb3974-bib-0008){ref-type="ref"}; Goyal et al., [2015a](#brb3974-bib-0012){ref-type="ref"}; Molina et al., [2015](#brb3974-bib-0016){ref-type="ref"}; Saver et al., [2015](#brb3974-bib-0021){ref-type="ref"}). MR Clean, IMS III, SWIFT PRIME, and ESCAPE were designed to determine safety and efficacy of endovascular treatment in AIS patients in addition to standard IV rt‐PA (0.9 mg alteplase per kilogram of body weight within a 4.5‐hr time window after onset of stroke; intervention group) compared to continued alteplase alone (Berkhemer et al., [2015](#brb3974-bib-0003){ref-type="ref"}; Broderick et al., [2013](#brb3974-bib-0004){ref-type="ref"}; Goyal et al., [2015a](#brb3974-bib-0012){ref-type="ref"}). Recent studies have found similar benefits of outcomes by the comparison of ET alone vs. ET with rt‐PA bridging (Broeg‐Morvay et al., [2016](#brb3974-bib-0005){ref-type="ref"}; Coutinho & Pereira, [2017](#brb3974-bib-0011){ref-type="ref"}; Coutinho et al., [2017](#brb3974-bib-0010){ref-type="ref"}; Rai et al., [2017](#brb3974-bib-0020){ref-type="ref"}; Tsivgoulis et al., [2016](#brb3974-bib-0024){ref-type="ref"}; Weber et al., [2017](#brb3974-bib-0025){ref-type="ref"}).

The aims of the present study are to compare the outcomes in patients who received ET in addition to standard IV rt‐PA therapy versus those who received only ET due to contraindications for IV rt‐PA.

2. METHODS {#brb3974-sec-0006}
==========

2.1. Study design {#brb3974-sec-0007}
-----------------

Between July 2011 and December 2016, all consecutive patients with AIS in the anterior circulation who underwent mechanical thrombectomy with or without IV rt‐PA at the departments of Neurology, University of Lübeck were included in this single‐center study and analyzed. Clinical severity was assessed based on the National Institutes of Health Stroke Scale \[NIHSS\] score. In accordance with national and international stroke guidelines, patients received IV rt‐PA at a dose of 0.9 mg per kilogram of body weight within 4.5 hr after onset of anterior circulation ischemic stroke. In patients with a wake‐up stroke or uncertain time frame since symptom onset IV rt‐PA could be administered nonetheless depending on image morphologic aspects in mandatorily required magnetic resonance imaging (MRI) or CT‐based Penumbra imaging with CBF/CBF mismatch in these cases. All included patients had occlusion of either the distal internal carotid artery or the first segment of the middle cerebral artery.

The primary outcomes of the study were the in‐hospital mortality and a favorable outcome at discharge from hospital, as measured on the modified Rankin Scale (mRS ≤2) (Bruening & Al‐Khaled, [2015](#brb3974-bib-0006){ref-type="ref"}). In addition, we assessed complications; symptomatic intracerebral hemorrhage (sICH) after treatment during hospitalization which was diagnosed according to ECASS III (Hacke et al., [2008](#brb3974-bib-0014){ref-type="ref"}). All patients included in the study were admitted to the stroke unit or intensive care unit (if an early tube removal was not possible) after intervention. All patients were treated by stroke neurologists and neuroradiologists. The study was part of the stroke registry as a benchmark project. The registration of stroke patients in the stroke registry is obligatory. Baseline and sociodemographic characteristics, such as gender, age, comorbid conditions, neurological deficits on admission, incident complications, and clinical findings, were identified from clinical records and the hospital information system and are presented in Table [1](#brb3974-tbl-0001){ref-type="table-wrap"}. The contraindications for the treatment with IV rt‐PA among patients who underwent only ET are listed in Table [2](#brb3974-tbl-0002){ref-type="table-wrap"}.

###### 

comparison of baseline data and treatment procedures between patients who underwent ET + IV rt‐PA and those who underwent ET only

  Baseline characteristics, treatment procedures, and outcomes   Treatment        *p* value        
  -------------------------------------------------------------- ---------------- ---------------- --------
  Age, mean (SD)                                                 69 (13)          68.7 (14)        .8
  Female sex (%)                                                 82 (57)          46 (46)          .3
  NIHSS, median, points (IQR)                                    13 (10--17)      13 (10--17)      .5
  ASPECTS, median                                                8 (7--9)         8 (6--9)         0.3
  Door to needle, median, minutes (IQR)                          28 (22--57)      ‐                
  SOI, median, minutes (IQR)                                     204 (155--262)   200 (151--248)   .24
  door to groin, median, minutes (IQR)                           88 (55--103)     83 (60--103)     .44
  Groin to reperfusion, median, minutes (IQR)                    50 (29--93)      52 (21--129)     .19
  Imaging to intervention, median, minutes (IQR)                 63 (40--100)     68 (45--90)      .7
  Wake up stroke                                                 21 (15)          22 (24)          .06
  In‐hospital stroke                                             9 (6)            24 (26)          \<.001
  Transported from other hospitals                               52 (36)          32 (35)          .7
  Medical history                                                                                  
   Previous stroke                                               36 (26)          32 (36)          .1
   Atrial fibrillation                                           66 (47)          50 (54)          .3
   Hypertension                                                  101 (72)         71 (78)          .3
   Diabetes mellitus                                             31 (22)          18 (20)          .7
   Hyperlipidemia                                                51 (36)          36 (40)          .6
   Previous smoking                                              22 (16)          16 (18)          .7
   Coronary heart disease                                        30 (21)          22 (24)          .6
  Premedication                                                                                    
   Statins                                                       29 (22)          29 (33)          .05
   Beta blocker                                                  71 (53)          47 (55)          .8
   Angiotensin‐converting enzyme inhibitor                       41 (31)          25 (29)          .8
   Antiplatelet treatment                                        50 (37)          42 (48)          .08
  Findings in initial CT scan and Angiography                                                      
   Early signs of ischemia                                       86 (61)          62 (67)          .3
   Dense artery sign                                             73 (51)          44 (48)          .6
   Middle cerebral artery occlusion                              132 (92)         82 (89)          .5
  Affected side                                                                                    
   Left                                                          76 (33)          52 (22)          .7
   Right                                                         65 (28)          40 (17)          
  Angiographic outcome (mTICI)                                                                     
   0                                                             4 (3)            4 (4)            .2
   1                                                             1 (0.7)          2 (2)            
   2a                                                            105 (73)         58 (63)          
   2b                                                            2 (1)            5 (5)            
   3                                                             31 (22)          23 (25)          
  Hospitalization, median, days (IQR)                            11 (8--16)       13 (8--19)       .8
  Treatment during hospitalization                                                                 
   ICA stenting                                                  31 (22)          22 (24)          .7
   Phenprocoumon                                                 6 (4)            6 (7)            .09
   DOAC                                                          25 (18)          10 (11)          .07
   Aspirin                                                       67 (48)          30 (33)          .028
   Clopidogrel                                                   28 (20)          20 (22)          .12
   Statins                                                       113 (80)         58 (64)          .013
  Primary outcomes                                                                                 
   In‐hospital mortality                                         13 (9)           18 (20)          .019
   Good Outcome (mRS0‐ ≤ 2)                                      73 (52)          21 (23)          \<.001
  Complications                                                                                    
   sICH                                                          3 (2)            7 (8.7)          .019
   Pneumonia during hospitalization                              72 (51)          45 (49)          .8

IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; DTN, door to needle time; SOI, symptom onset to intervention time; DOAC, direct oral anticoagulants (Dabigatran, Rivaroxaban, Apixaban); sICH, symptomatic intracerebral hemorrhage.

John Wiley & Sons, Ltd

###### 

Contraindications for intravenous treatment with rt‐PA in patients received only ET

  Contraindications                                                                *N* (%)
  -------------------------------------------------------------------------------- -----------
  Symptom onset to expected IVT \>4.5 hr (including unknown Symptom onset time)s   32 (11)
  Demarcated infarction                                                            22 (7.5)
  Expanded early signs of infarction                                               8 (2.7)
  History of recent surgery                                                        13 (4.5)
  History of recent infarction                                                     10 (3.4)
  Recent trauma or fracture                                                        5 (1.7)
  History of recent bleeding                                                       9 (3.1)
  Peri‐interventional during coronary angiography                                  1 (0.3)
  Thrombus occurred during angiography                                             2 (0.6)
  Oral anticoagulation therapy                                                     41 (14.5)

IVT indicates intravenous thrombolysis.

John Wiley & Sons, Ltd

2.2. Endovascular treatment {#brb3974-sec-0008}
---------------------------

Following their admission to hospital, patients with stroke underwent a computed tomography (CT) scan of the brain with CT angiography. The decision to carry out ET was made by a stroke neurologist and a neuroradiologist. All ETs were performed as standard procedures under general anesthesia via a transfemoral approach. The majority of patients were treated with stent retrievers in combination with proximal or distal aspiration, only very few by direct aspiration with the Penumbra System^®^. The most commonly used stent‐retriever in our study was the Trevo^®^‐Stent (Stryker), which has been chosen in majority of all thrombectomies. Other retrievers that have been used were the Solitaire Device (ev3), the ReViveSE^™^ Device (Codman), and the 3D Separator (Penumbra). Depending on the anatomy and concomitant pathologies (e.g., carotid artery stenosis), thrombectomies were either performed with proximal aspiration via an 8F balloon guide catheter (Cello^®^, ev3) or distal aspiration during stent retrieval with 5MAX, 5MAX ACE (Penumbra) or Sofia^®^ (MicroVention) distal access catheter. The Penumbra aspiration pump was used to ensure continuous reverse flow, respectively, flow arrest during clot retrieval. The average waiting time for clot integration into the struts was 3 min. The success of the procedure has been assessed by modified treatment in cerebral ischemia (mTICI)‐Score.

2.3. Statistics {#brb3974-sec-0009}
---------------

We used the Statistical Product and Service Solutions (SPSS) program (version 22) to analyze the data. The data were described with mean and SD values for continuous variables, median and interquartile range (IQR) values for scores, and absolute numbers and percentages for nominal and categorical variables. We performed a chi‐square test to determine the correlation between categorical variables, a *t* test between continuous variables, and a Mann--Whitney test between scores. Logistic regression was carried out to estimate the odds ratios (ORs) for in‐hospital mortality and favorable outcome (mRS ≤2). The logistic regression was adjusted for age, sex, NIHSS score at admission, and medical history. The variables such as sex, age, arterial hypertension, diabetes mellitus, hypercholesterolemia, previous stroke, and atrial fibrillation were entered into the logistic regression model. A *p* value \<.05 was considered significant.

3. RESULTS {#brb3974-sec-0010}
==========

Of 236 patients (mean age, 69.0 ± 13 years; 46% women), 144 patients received ET in addition to medical therapy with IV rt‐PA (ET + IV rt‐PA), whereas 92 patients underwent ET only due to contraindications for IV rt‐PA.

A comparison of baseline characteristics at admission between the groups is shown in Table [1](#brb3974-tbl-0001){ref-type="table-wrap"}.

The parameters leading to a contraindication for IV rt‐PA treatment are shown in Table [2](#brb3974-tbl-0002){ref-type="table-wrap"}. The most common reasons were pre‐treatment with oral anticoagulants (14.5%), a prolonged time window (time from symptom onset possibly or definitely \>4.5 hr, 11%), and a visible infarct demarcation or suggestive of a subacute infarction with an onset \>4.5 hr. Nevertheless, 50% of 42 patients with wake up stroke i.v. rt‐PA was administered off‐label based on penumbra imaging with perfusion‐weighted CT or MRI. The median mRS at admission was 5 (IQR = 4--5) among the whole cohort and decreased significantly (*p *\<* *.001) after treatment to 3 (IQR = 2--5) at discharge. The change of mRS from admission to discharge is shown in Figure [1](#brb3974-fig-0001){ref-type="fig"}, by dividing the group with rt‐PA versus without. In both groups, we found a significant decrease in mRS from admission to discharge; among patients who received rt‐PA therapy (from 5 to 2; *p *\<* *.001) and among patients with only ET (from 5 to 4; *p *\<* *.001).

![Change of mRS from admission to discharge as well as a comparison of mRS score between admission and discharge. (a) In‐patients with only Endovascular Therapy. (b) In‐patients with IV‐rt‐PA and Endovascular Therapy. (c) Median mRS change in both groups](BRB3-8-e00974-g001){#brb3974-fig-0001}

By comparing the two groups, with rt‐PA vs. without, the rate of favorable functional outcome at discharge from hospital (mRS ≤ 2) was higher (51.4% versus 23.1%, respectively; *p *\<* *.001) and in‐hospital mortality was lower (9% versus 19.6%, respectively; *p *=* *.019) among patients who underwent ET + IV rt‐PA versus those who underwent ET only (Figure [2](#brb3974-fig-0002){ref-type="fig"}).

![Comparison of favorable outcome, in‐House mortality and symptomatic intracerebral hemorrhage (SICH) between ET with rt‐PA versus without](BRB3-8-e00974-g002){#brb3974-fig-0002}

Furthermore, the frequency of sICH was lower in patients with IV rt‐PA (2.1% versus 8.7%; *p *=* *.019) compared to the patients who underwent ET only (Figure [2](#brb3974-fig-0002){ref-type="fig"}). The recanalization of the anterior circulation determined with mTICI did not show a significant difference between groups (Table [1](#brb3974-tbl-0001){ref-type="table-wrap"}).

Adjusted logistic regression revealed that treatment with ET + IV rt‐PA was associated with an increased rate of favorable functional outcome at discharge (OR, 4.3; 95% CI, 2.2--8.5; *p *\<* *.0001), whereas no differences were found among the in‐hospital mortality (OR, 0.74; 95% CI, 0.3--1.9; *p *=* *.76) and rate of sICH (OR,0.3; 95% CI, 0.07--1.2; *p *=* *.09).

A difference in the recanalization rate assessed by mTICI scores was found similar in both groups (Table [1](#brb3974-tbl-0001){ref-type="table-wrap"}). During a median hospitalization of 11 days, the occurrence of stroke‐related pneumonia did not differ between patients who underwent ET + IV rt‐PA and those who underwent ET only (51% versus 49%, respectively; *p *=* *.8).

4. DISCUSSION {#brb3974-sec-0011}
=============

In the present study, 61% of AIS patients received an intervention with ET in addition to IV rt‐PA therapy, whereas 39% underwent ET only. For patients who underwent ET only, this was the only option for stroke therapy because of existing contraindications of treatment with IV rt‐PA (Table [2](#brb3974-tbl-0002){ref-type="table-wrap"}). Of these patients, 18% presented with wake‐up stroke, and 17% were medicated with oral anticoagulants.

The severity of stroke and the most common baseline characteristics did not differ between the two groups. In addition, the median time of 200 min between symptom onset and beginning of intervention (groin puncture and placement of thrombectomy device) was comparable to those of previous investigations(Campbell et al., [2015](#brb3974-bib-0008){ref-type="ref"}; Saver et al., [2015](#brb3974-bib-0021){ref-type="ref"}), and showed no difference between patients who underwent ET + IV rt‐PA and those who underwent ET only. About 36% of patients primarily presented to other hospitals and then they were immediately transported to our hospital to receive extended stroke care. The rate of transferred patients was similar in both treatment groups.

Among the entire cohort, an improvement of neurological deficits measured on the mRS score was found, whereas the rate of improvement of the neurological deficits was notably higher in the patients group who received additional rt‐PA treatment. Implementation of rt‐PA was associated with a better outcome (OR, 4.3). Comparable to other studies, neither in hospital mortality nor sICH did show any difference in the logistic regression analysis (Al‐Khaled, Eggers, & Qug, [2014](#brb3974-bib-0001){ref-type="ref"}; Al‐Khaled, Matthis, & Eggers, [2014](#brb3974-bib-0002){ref-type="ref"}; Berkhemer et al., [2015](#brb3974-bib-0003){ref-type="ref"}; Bruning & Al‐Khaled, [2015](#brb3974-bib-0007){ref-type="ref"}).

The finding of a better outcome in patients with additional i.v. thrombolysis has to be interpreted with caution. All contraindications to i.v. thrombolysis (extended time window, anticoagulation, surgery) are likely to contribute to worsening of outcome in patients with acute stroke. In addition, recent data suggest a better outcome after endovascular treatment in patients receiving conscious sedation compared to patients receiving general anesthesia (Campbell et al., [2018](#brb3974-bib-0009){ref-type="ref"}). The patients in our study were all treated under general anesthesia. However, a relevant systematic group bias is improbable because general anesthesia would affect both groups.

Strengths of the present study are its monocenter setting, in that all patients received treatment from the same medical team and the first study to compare the outcomes of patients who underwent ET + IV rt‐PA and those who underwent ET only due to contraindications for rt‐PA. In previous studies, notably the study by Goyal et al. ([2015b](#brb3974-bib-0013){ref-type="ref"}), approximately, 25% of patients did not receive treatment with IV alteplase. Moreover, in the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) investigation, 10% of patients who had undergone a thrombectomy did not receive medical treatment with rt‐PA. In both studies, a reduced benefit associated with the performance of only ET was not found (Berkhemer et al., [2015](#brb3974-bib-0003){ref-type="ref"}; Goyal et al., [2015a](#brb3974-bib-0012){ref-type="ref"}). However, a recent meta‐analysis found a favorable outcome in patients with additional i.v. Thrombolysis (Mistry et al., [2017](#brb3974-bib-0015){ref-type="ref"}). Our study adds further support to that found by the meta‐analysis by Mistry et al., [2017](#brb3974-bib-0015){ref-type="ref"} and to the recent study by Nogueira et al. ([2018](#brb3974-bib-0017){ref-type="ref"}) showing better outcomes among stroke patients who underwent ET within 6--24 hr after symptom onset.

Our study also has several limitations: Its design was not randomized. Thus, the finding of a better outcome in patients with additional i.v. thrombolysis has to be interpreted with caution. All contraindications to i.v. thrombolysis (extended time window, anticoagulation, surgery) are likely to contribute to a worsening of outcome in patients with acute stroke.

Despite these limitations, it is a single‐center real‐life study showing that medical treatment with IV rt‐PA before thrombectomy may improve functional outcome compared with the interventional treatment alone.
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